32.jpg)
56.jpg)
NRX-201
Exhibitor
Area of exhibition:
Stand
Knowledge-generating body:
Servatrix Biomed S.L. originates from the Autonomous University of Madrid (UAM), where its core scientific knowledge and technology were generated through long-term academic research in biomedical sciences, particularly in the NRF2 pathway and chronic liver disease.
Servatrix Biomed S.L.’s prototype/product is a proprietary NRF2-activating lead compound, currently in preclinical development, designed for the treatment of MASH/NASH.
Country:
Spain
Region:
Community of Madrid
Sectors:
Chemicals
Industrial Biotech
SDG:
SDG03: Good health and well-being
Video Link:
View video hereApplications
The prototype/product developed by Servatrix Biomed S.L. is intended to be used as a prescription therapeutic drug for patients with MASH/NASH, with the practical application of reducing liver fat, inflammation, and oxidative stress to slow or halt disease progression and prevent severe outcomes such as fibrosis, cirrhosis, and liver failure.
